Description
NURECA LIMITED has fixed December 12, 2025 as the record date to determine shareholders eligible to participate in the buyback offer.
Summary
NURECA LIMITED (Scrip Code: 543264) has announced a buyback of equity shares through a tender offer and has fixed December 12, 2025 as the record date. This date will determine which shareholders are eligible to participate in the buyback offer. The ex-entitlement date is also December 12, 2025 (Settlement No. DR-776/2025-2026).
Key Points
- Company: NURECA LIMITED (Scrip Code: 543264)
- Record Date: December 12, 2025
- Ex-Entitlement Date: December 12, 2025
- Settlement Number: DR-776/2025-2026
- Purpose: To determine entitlement and names of equity shareholders eligible to participate in the buyback offer
- Security Type: Dematerialised securities in rolling settlement segment
- Notice Number: 20251210-13
Regulatory Changes
No regulatory changes introduced. This is a standard corporate action notice regarding a buyback offer.
Compliance Requirements
- Trading members of BSE must take note of the record date and ex-entitlement date
- Only shareholders holding shares as of the record date (December 12, 2025) will be eligible to participate in the buyback
- Shares will trade ex-entitlement from December 12, 2025
Important Dates
- Notice Date: December 10, 2025
- Record Date: December 12, 2025
- Ex-Entitlement Date: December 12, 2025
- Settlement Number: DR-776/2025-2026
Impact Assessment
Shareholder Impact: Eligible shareholders will have the opportunity to tender their shares in the buyback offer, potentially realizing value at a premium to market price. Only those holding shares on the record date will be eligible.
Market Impact: The stock will trade ex-entitlement from December 12, 2025, meaning buyers purchasing shares on or after this date will not be eligible for the buyback. This may result in price adjustments on the ex-date.
Trading Impact: Trading members need to ensure proper handling of trades around the record date and communicate eligibility criteria to clients holding NURECA shares.
Impact Justification
Company-specific buyback announcement affecting NURECA shareholders. Medium impact as it provides shareholders an exit opportunity at a premium, but limited to single company.